Clincosm LogoSign in Get a demo

Clinical Characteristics for the Critical Ill Patients With Klebsiella Pneumoniae Infection

Sponsor
Fujian Provincial Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT04404582
Collaborator
(none)
546
Enrollment
61.9
Actual Duration (Months)

Study Details

Study Description

Brief Summary

The detection of Klebsiella pneumoniae virulence gene and antibiotics resistance gene takes a long time and high cost with equipment requirements. Distinguishing the Klebsiella pneumoniae by gene were late for clinical treatment. Therefore, the investigators aim to study the clinical characteristics of critically ill patients with Klebsiella pneumoniae infection which expressed different drug sensitivity test results.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Clinical data of adult patients in integrated ICUs of 6 hospitals of Fujian Province China from January 2015 to July 2019 were collected, who had been examined for sputum, urine, blood, pleural effusion, ascites, cerebrospinal fluid and wound secretions and other body fluid samples. And the results showed that Klebsiella pneumoniae was positive, including demographic data, underlying disease status, drug sensitivity test, infection-related indicators, life support, prognostic indicators.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    546 participants
    Observational Model:
    Other
    Time Perspective:
    Retrospective
    Official Title:
    Analysis of the Clinical Characteristics for the Critical Ill Patients With Klebsiella Pneumoniae Infection: A Multi-center Research in the Intensive Care Units
    Actual Study Start Date :
    Jan 1, 2015
    Actual Primary Completion Date :
    Jul 31, 2019
    Actual Study Completion Date :
    Feb 28, 2020

    Arms and Interventions

    Arm Intervention/Treatment
    Klebsiella pneumoniae

    patients with Klebsiella pneumoniae infection had different results of the drug sensitivity test. we compared the prognosis of these patients.

    Outcome Measures

    Primary Outcome Measures

    1. prognostic indicators [30 day]

      30-day survival rate

    2. ICU stays [about a mouth]

      the length that patients stay in ICU

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    • Adult whose body fluid were sampled during ICU stay and Klebsiella pneumoniae was detected, followed by drug sensitivity test (including reporting the test results after the patient was transferred out of ICU or died).
    Exclusion Criteria:

    • Age were less than 18 years old;

    • Patients stayed in ICU was less than 48 hours.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Fujian Provincial Hospital

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Xiuling Shang, associate senior doctor, Fujian Provincial Hospital
    ClinicalTrials.gov Identifier:
    NCT04404582
    Other Study ID Numbers:
    • K2019-06-031
    First Posted:
    May 27, 2020
    Last Update Posted:
    May 27, 2020
    Last Verified:
    May 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Pneumonia

    Study Results

    No Results Posted as of May 27, 2020